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Improvement in Diagnosis of Histoplasma Meningitis 
by Combined Testing for Histoplasma Antigen and 
Immunoglobulin G and Immunoglobulin M Anti-
Histoplasma Antibody in Cerebrospinal Fluid
Karen C. Bloch,1 Thein Myint,2 Luke Raymond-Guillen,3 Chadi A. Hage,3 Thomas E. Davis,3 Patty W. Wright,1 Felicia C. Chow,4 Laila Woc-Colburn,5  
Raed N. Khairy,6 Alan C. Street,7 Tomotaka Yamamoto,8 Amanda Albers,9 and L. Joseph Wheat9
1Vanderbilt University School of Medicine, Nashville, Tennessee; 2University of Kentucky School of Medicine, Lexington; 3Indiana University School of Medicine, Indianapolis; 4School of Medicine, 
University of California, San Francisco; 5Baylor College of Medicine, Houston, Texas; 6Sparks Center for Infectious Diseases, Fort Smith, Arkansas; 7Royal Melbourne Hospital, Parkville, Victoria, 
Australia; 8University of Tokyo Hospital, Japan; and 9MiraVista Diagnostics, Indianapolis, Indiana
Background. Central nervous system (CNS) histoplasmosis is a life-threatening condition and represents a diagnostic and ther-
apeutic challenge. Isolation of Histoplasma capsulatum from cerebrospinal fluid (CSF) or brain tissue is diagnostic; however, culture 
is insensitive and slow growth may result in significant treatment delay. We performed a retrospective multicenter study to evaluate 
the sensitivity and specificity of a new anti-Histoplasma antibody enzyme immunoassay (EIA) for the detection of IgG and IgM anti-
body in the CSF for diagnosis of CNS histoplasmosis, the primary objective of the study. The secondary objective was to determine 
the effect of improvements in the Histoplasma galactomannan antigen detection EIA on the diagnosis of Histoplasma meningitis.
Methods. Residual CSF specimens from patients with Histoplasma meningitis and controls were tested for Histoplasma anti-
gen and anti-Histoplasma immunoglobulin G (IgG) and immunoglobulin M (IgM) antibody using assays developed at MiraVista 
Diagnostics.
Results. A total of 50 cases and 157 controls were evaluated. Fifty percent of patients with CNS histoplasmosis were immuno-
compromised, 14% had other medical conditions, and 36% were healthy. Histoplasma antigen was detected in CSF in 78% of cases 
and the specificity was 97%. Anti-Histoplasma IgG or IgM antibody was detected in 82% of cases and the specificity was 93%. The 
sensitivity of detection of antibody by currently available serologic testing including immunodiffusion and complement fixation was 
51% and the specificity was 96%. Testing for both CSF antigen and antibody by EIA was the most sensitive approach, detecting 98% 
of cases.
Conclusions. Testing CSF for anti-Histoplasma IgG and IgM antibody complements antigen detection and improves the sensi-
tivity for diagnosis of Histoplasma meningitis.
Keywords. histoplasmosis; meningitis; antibody; antigen; diagnosis. 
Central nervous system (CNS) involvement is present in 
5%–10% of patients with disseminated histoplasmosis [1, 2]. 
Clinical presentations include meningitis, hydrocephalus, brain 
or spinal cord mass lesions, stroke, and encephalitis. CNS infec-
tion may occur with concomitant pulmonary or disseminated 
disease or may be present in isolation. Neurologic involvement 
may be detected at the initial presentation or may represent 
relapse after treatment of disseminated or pulmonary histoplas-
mosis. The time course may be rapid or protracted over several 
years [3]. Given these heterogeneous presentations, the disease 
is often unrecognized and diagnosis and treatment delayed, 
resulting in neurologic complications or death.
Even when CNS involvement is suspected, laboratory confir-
mation can be challenging. In the 2 largest reviews, cerebrospi-
nal fluid (CSF) cultures were positive in only 28% of patients [1, 
2], and growth was delayed for several weeks after presentation. 
Diagnosis is clinically important, as these patients require longer 
courses and higher doses of liposomal amphotericin B than 
patients with disseminated disease not involving the CNS [4].
The limitations of fungal cultures have resulted in attempts to 
identify more sensitive and rapid diagnostics for CNS histoplas-
mosis. Diagnostic techniques that have improved performance 
characteristics include detection of antigen in CSF using radi-
oimmunoassay (RIA) and of antibody by complement fixation 
(CF) [5]. Testing of CSF using these techniques improved the 
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sensitivity to 67%—significantly better than culture, but still 
imperfect [1]. Detection of anti-Histoplasma antibodies by RIA 
had a sensitivity of 89% [6], but this assay was never validated 
or offered for clinical testing.
The current Histoplasma antigen detection enzyme immuno-
assay (EIA) [7] is more sensitive than the original RIA [1] and 
antibody detection by EIA is more sensitive than immunodiffu-
sion (ID) or CF [8]. With the availability of these newer diag-
nostics, we evaluated the accuracy of the antigen and antibody 
EIAs for the diagnosis of Histoplasma meningitis.
METHODS
Study Specimens
The study sample consisted of residual CSF from patients 
who had specimens submitted to MiraVista Diagnostics for 
Histoplasma antigen testing between 2000 and 2015. The study 
population comprised these groups (Figure 1):
1. Clinically suspected case and control specimens (n = 155): 
This group included all patients with CSF samples sub-
mitted to MiraVista Diagnostics for Histoplasma antigen 
testing between 2014 and 2015 from Indiana University 
Medical Center (IUMC), University of Kentucky Medical 
Center (UKMC), and Vanderbilt University Medical 
Center (VUMC), areas that are highly endemic for histo-
plasmosis. CSF obtained for Histoplasma antigen testing 
performed as part of clinical care specimens were stored 
frozen at MiraVista Diagnostics and prospectively tested 
for Histoplasma antibodies as part of the study protocol. 
Investigators blinded to results of the study-related testing 
performed chart review. Based on case definitions below, 20 
patients met criteria for CNS histoplasmosis, and 135 were 
included as controls.
2. Individual case specimens (n  =  30): This group was com-
posed of residual CSF samples from 30 patients with pre-
viously diagnosed CNS histoplasmosis for whom treating 
physicians consulted with the medical director at MiraVista 
Diagnostics and provided clinical information.
3. Fungal meningitis not suspected (n  =  22): This group 
included residual CSF specimens from patients at IUMC in 
whom fungal meningitis was not suspected and Histoplasma 
antigen testing was not ordered. These patients, in addition 
to the 135 patients in the clinically suspect group who did 
not meet case criteria, comprised the control group.
Case Definitions
Patients were categorized as CNS histoplasmosis cases if they 
had CNS inflammation (defined as CSF white blood cell count 
≥5 cells/μL) or brain imaging abnormalities and supporting 
laboratory studies:
• Confirmed: isolation of Histoplasma capsulatum from CSF;
• Probable: detection of Histoplasma antigen by EIA or 
anti-Histoplasma antibodies in the CSF by ID or CF;
• Possible: pulmonary or disseminated histoplasmosis with-
out laboratory confirmation of CNS involvement (negative 
or absent culture, microscopy, detection of antigen or detec-
tion of antibody by ID or CF in the CSF). Similar classifi-
cation has been previously described for histoplasmosis [1] 
and other endemic mycosis [9, 10].
Figure 1. The study population and classification of cases and controls. Individual case specimens: patients with central nervous system (CNS) histoplasmosis accrued 
through clinical testing at MiraVista Diagnostics from outside institutions besides Indiana University Medical Center (IUMC), University of Kentucky Medical Center (UKMC), 
and Vanderbilt University Medical Center (VUMC). Clinical suspected specimens: unique patients with specimen submitted for testing at MiraVista Diagnostics from IUMC, 
UKMC, and VUMC based on clinical concern for CNS histoplasmosis. This group includes cases that met the criteria for diagnosis of meningitis (cases) and patients that 
did not meet those criteria (controls). Alternative diagnosis specimens: patients (controls) with no clinical suspicion for CNS histoplasmosis, in whom no specimens were 
submitted for testing at MiraVista Diagnostics but from whom cerebrospinal fluid specimens were obtained from the microbiology laboratories at IUMC.
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Controls included patients with either:
• Pulmonary or disseminated histoplasmosis [7] without CNS 
involvement (no clinical findings for meningitis, no pleocy-
tosis or CNS imaging abnormalities, no diagnosis of or treat-
ment for CNS histoplasmosis);
• Negative testing for histoplasmosis (either with or without 
CSF pleocytosis).
Laboratory Methods
The EIA for detection of anti-Histoplasma antibodies has been 
described [8]. CSF was diluted 25-fold in StartingBlock buffer 
(Thermo Scientific, Rockford, Illinois). Results were expressed 
semi-quantitatively as EIA units by comparison to a standard 
curve. Results >10 units were considered positive and results 
<7.9 units were classified as negative. Results between 8.0 and 
9.9 units were categorized as indeterminate but for analysis 
were classified as negative.
The Histoplasma antigen EIA was performed as previously 
reported for serum [7]. Pretreatment of the CSF with eth-
ylenediaminetetraacetic acid (EDTA) was implemented in 
2009 [11]. One hundred microliters of 4% EDTA was added 
to 300  µL of CSF, and the mixture was vortexed and placed 
in a heat block at 104°C for 6 minutes. The heat-treated CSF 
was centrifuged and the supernatant was tested for antigen. 
The purpose of this step was to dissociate antigen–antibody 
immune complexes and denature the antibody, freeing the 
antigen for detection by EIA.
An optical density above the cutoff for positivity was con-
sidered positive. Results above the 0.4  ng/mL standard were 
reported as ng/mL. Those between the cutoff and the 0.4 ng/
mL standard were reported as positive, below the limit of quan-
tification (LOQ). Results above the 19  ng/mL standard were 
reported as positive, above the LOQ. Levels below the LOQ 
were assigned a concentration of 0.3 ng/mL and those above the 
LOQ were assigned a value of 19.0 ng/mL for statistical analysis 
and illustration.
Histoplasma antibody testing by CF or ID was performed as 
part of clinical care through commercial laboratories employed 
by the facility at which the patient was evaluated.
Statistical Analysis
SigmaPlot software (Systat Software, San Jose, California) was 
used for transformation of optical density values into EIA 
units. MedCalc for Windows version 12.3.0 (Ostend, Belgium) 
was performed to calculate predictive values for 155 clini-
cally suspected specimens, representing all patients at IUMC, 
UKMC, and VUMC for whom CSF was submitted to MiraVista 
Diagnostics for Histoplasma antigen testing. A χ2 analysis was 
used to compare subgroups using MedCalc software. P values 
<.05 were considered significant.
Ethical Considerations
The study was approved by the institutional review boards 
(IRBs) at the following institutions: IUMC, UKMC, VUMC, 
and the University of California, San Francisco Medical Center. 
IRB committees at the other institutions reviewed the protocol 
and concluded that IRB approval was not required. Inclusion of 
a case from University of Tokyo Hospital was approved by the 
Hospital Ethics Committee.
RESULTS
A comparison of baseline characteristics is presented in Table 1. 
There were 9 confirmed cases, 36 probable cases, and 5 possible 
cases. The median age and sex and presence of immunocompro-
mising conditions or medications were similar between groups, 
but cases were less likely to have comorbid diseases than controls.
Fungal culture of CSF was positive for H. capsulatum in 19% 
of cases (Table 2). Cultures were positive more often in the indi-
vidual cases (28.6%) than the clinically suspected cases (5.3%), 
but the difference was not significant (P = .1066).
Antigen was detected in the CSF in 78% of cases, including 
78% of confirmed cases, 89% of probable cases, and 0% of pos-
sible cases. To avoid incorporation bias, we also calculated the 
sensitivity of CSF antigen testing after excluding 23 cases in 
which antigen testing was the sole means of laboratory diag-
nosis, resulting in a sensitivity of 78% in confirmed or probable 
cases established through culture or antibody testing by ID or 
CF. Antigen was detected in 33 of 39 (85%) of the CSF specimens 
that were treated with EDTA compared with 5 of 11 (45%) that 
were tested before the EDTA treatment step was implemented 
(P = .0187). Quantitative antigen concentrations are shown in 
Figure 2. Histoplasma antigen was detected in urine or serum in 
36 of 47 (77%) cases.
Elevated levels of IgG or IgM anti-Histoplasma antibodies 
measured by EIA were present in 82% of cases. These results 
were not considered as the basis for diagnosis to avoid incor-
poration bias. Antibody was detected by EIA less often in 
Table 1. Baseline Characteristics of Cases and Controls
Variable
Cases
(n = 50)
Controls
(n = 157) P Value
Age, y, median (range) 43.0 (1 mo–77 y) 49.0 (1 mo–85 y) .14
Sex, male 30 (60) 91 (58) .93
Immunocompromisea 25 (50) 67 (42.7) .46
Nonimmunocompromising 
medical conditionsb
7 (14) 69 (43.9) .0003
No recognized underlying 
condition
18 (36) 21 (13.4) .0008
Data are presented as No. (%) unless otherwise indicated.
aImmunodeficiency state or immunosuppressive therapy. Immunocompromising condi-
tions included AIDS in 13, solid organ transplantation in 6, immunosuppressive therapy 
for inflammatory disorders in 5, and an uncharacterized immunodeficiency in 1 patient.
bNonimmunocompromising conditions included cerebral palsy, chronic pulmonary disease, 
hepatitis C, malignancy, pregnancy, and head trauma in 1 patient each.
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immunocompromised than nonimmunocompromised patients 
(Table 3). The sensitivity for detection of antibodies by ID or CF 
(51%) was lower than by EIA (P = .0029). Histoplasma antigen or 
anti-Histoplasma antibodies by EIA were present in the CSF in 
98% cases. The negative predictive value for combined antigen 
and antibody testing by EIA was 100% (Table 2). Quantitative 
antibody concentrations by EIA are shown in Figure 2.
IgG or IgM anti-Histoplasma antibodies were detected in the 
CSF in 7 of 9 confirmed cases (78%), 27 of 32 probable cases (84%), 
and 3 of 4 possible cases (75%). Testing was unable to be performed 
in 5 patients due to insufficient specimen. If the possible cases are 
excluded from the analysis, the sensitivity for detection of antibod-
ies by EIA was 83%, compared to 82% if they are included.
The specificity for detection of antigen in the CSF was 97% 
(Table  2). Five controls had detectable antigen in the CSF. 
Diagnosis included Blastomyces meningitis and pulmonary or 
disseminated histoplasmosis without evidence of CNS involve-
ment in 2 patients each (Supplementary Table 1). A fifth patient, 
who was receiving antibiotics for Helicobacter pylori gastritis, 
developed fever, altered mental status, rash, and eosinophilia. 
CSF leukocyte count was 4 cells/µL, the glucose was 55 mg/dL, 
and the protein was 28 mg/dL. No testing for fungal infection 
was ordered, but residual CSF was obtained as an “alternative 
diagnosis” control. Antigen was positive at 2.2 ng/mL but below 
the LOQ when repeated.
Specificity for detection of anti-Histoplasma IgG or IgM anti-
bodies by EIA was 93% and the positive predictive value (PPV) 
was 52% (Table  2). Diagnoses in the controls with detectable 
antibodies (Supplementary Table  1) included cryptococcal or 
Blastomyces meningitis in 1 patient each; histoplasmosis not 
involving the brain or meninges in 3 patients; bacterial menin-
gitis in 2 patients; and tuberculous meningitis, neurosarcoido-
sis, melanoma involving the brain, and migraine in 1 patient 
each. The specificity and PPV for detection of antibodies by ID 
were 100% (Table 2).
Figure 2. Histoplasma antigen and anti-Histoplasma antibody results in cere-
brospinal fluid in the cases and controls. For antigen testing, results <0.3 ng/mL 
(indicated by the solid line shown at 0.3 ng/mL) were considered negative, whereas 
results of ≥0.3 ng/mL were positive, below the limit of quantification at 0.4 ng/
mL. Antigen results >19 ng/mL were above the limit of quantification. Results 
indicated by the number at the bottom of each of the antigen columns represent 
negative results because the space below the line designating the cutoff for posi-
tivity would not permit depiction of individual results for the controls. For antibody 
testing, results <8 units (indicated by broken horizontal line) were negative, results 
between 8 and 9.9 units were indeterminate, and results of 10 units (indicated by 
solid horizontal line shown at 10 units) or higher were positive. Results indicated 
by the number at the bottom of each of the antibody columns represent negative 
results because the space below the line designating the cutoff for positivity would 
not permit depiction of individual results for the controls, and the 32 cases in the 
immunoglobulin M column. Abbreviations: IgG, immunoglobulin G, IgM, immuno-
globulin M; n, number of patients with negative results .
Table  3. Comparison of Diagnostic Testing in Immunocompromised 
and Nonimmunocompromised Patients With Central Nervous System 
Histoplasmosis
Diagnostic test Immunocompromised Nonimmunocompromised P Value
Culture 5/23 (21.7) 4/24 (16.7) .9484
Antigen 22/25 (88) 17/25 (64) .0978
ID or CF antibody 8/21 (38.1) 14/22 (63.6) .0716
EIA IgG or IgM 
antibody
15/22 (68.2) 22/23 (95.7) .0430
Antigen or anti-
body EIA
23/25 (92) 25/25 (100) .4750
Antigen or anti-
body ID or CF
19/20 (95) 20/22 (90.9) .9326
Abbreviations: CF, complement fixation; EIA, enzyme immunoassay; ID, immunodiffusion; 
IgG, immunoglobulin G; IgM, immunoglobulin M.
Table 2. Histoplasma Diagnostic Testing in the Cerebrospinal Fluid
Test Sensitivitya Specificityb PPV, % NPV, %
Culture 9/47 (19.1) 119/119 (100)c 100 91.8
Antigen 39/50 (78) 140/145 (96.6) 71.8 97.5
EIA IgG antibody 37/45 (82.2) 145/153 (94.8) 55.9 97.9
EIA IgM antibody 14/45 (31.1)  149/153 (97.4) 57.1 92.7
EIA IgG or IgM antibodyd 37/45 (82.2) 142/153 (92.8) 52.1 97.9
Antigen or antibody EIAe 48/49 (98.0) 139/153 (90.8) 54.7 100
ID antibody 19/43 (44.2) 13/13 (100) 100 94.1
CF antibody  5/10 (50) 13/14 (92.9) 43.9 94.4
ID or CF antibodyd 22/43 (51.2) 22/23 (95.6) 56.4 94.6
Antigen or antibody ID or CFe 39/43 (90.7) 18/23 (78.3) 31.7 98.7
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: CF, complement fixation; EIA, enzyme immunoassay; ID, immunodiffusion; 
IgG, immunoglobulin G; IgM, immunoglobulin M; NPV, negative predictive value; PPV, pos-
itive predictive value.
aPositive test results/patients with central nervous system (CNS) histoplasmosis.
bNegative test result/patients without CNS histoplasmosis.
cDenominators vary because specimen volume was inadequate to perform the anti-His-
toplasma antibody EIA and culture or antibody detection by ID and CF testing was not 
performed as part of clinical care in some patients.
dComparison of antibody detection by EIA and ID or CF: sensitivity, P = .0029; specificity, 
P = 1.000.
eComparison of antigen or antibody detection by EIA and antigen or antibody by ID or CF: 
sensitivity, P = .1813; specificity, P = .0801.
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DISCUSSION
Information on the accuracy of the diagnostic tests for 
Histoplasma meningitis is meager, and much of what has been 
published predates currently available assays [1, 2]. The largest 
single-institution study evaluated 18 patients with CNS his-
toplasmosis and reviewed 86 additional cases reported in the 
literature [1]. In this population, antigen was detected in the 
CSF in 40%, antibody by ID or CF in 62%, and either antigen 
or antibody was detected in 67% of patients [1]. The antigen 
assay used in that study was an RIA developed in 1985 [12]. The 
antigen assay has evolved to a fourth-generation EIA [7] that 
incorporates EDTA treatment [11]. Using EDTA treatment, 
the sensitivity of antigen detection in the CSF was 85% in the 
current study. Similarly, the use of the newly developed anti-
body EIA improved the sensitivity for antibody detection from 
51% by ID or CF to 82% by EIA. The combined sensitivity for 
Histoplasma antigen and anti-IgG or IgM antibody detection by 
EIA was 98% and the negative predictive value was 100%.
Incorporation bias caused by use of the antigen results for 
diagnosis of Histoplasma meningitis hampers assessment of its 
sensitivity. However, the sensitivity was the same (78%) in cases 
including antigen detection as the basis for diagnosis and in a 
subset in which antigen detection alone was excluded as labora-
tory basis for diagnosis. Also, no differences in sensitivity for any 
of the diagnostic tests were observed in the clinically suspected 
cases, which included all patients in whom antigen testing was 
ordered and the individual cases, in which enrollment bias was 
more likely (Supplementary Table  2). Inclusion of antigen and 
antibody results using the EIA as the basis for diagnosis reduced 
the proportion of cases categorized as possible CNS histoplasmo-
sis from 33% in the earlier study [1] to 2% in this study (Table 2).
The possible category includes 5 patients in who histoplas-
mosis was identified but CNS involvement was not established 
by culture, cytopathology, or detection of antigen or antibody in 
the CSF. A similar approach was used previously in CNS histo-
plasmosis [1], blastomycosis [9], and coccidioidomycosis [10]. 
Exclusion of the possible cases did not impact the sensitivity 
of antigen or antibody detection for diagnosis of CNS histo-
plasmosis. Noteworthy is that the possible category used in this 
study differs from that described in the guidelines for diagnosis 
of invasive mycoses, in which possible cases had no mycologic 
evidence for diagnosis [13].
Schestatsky et al identified 17 cases of meningitis among 217 
patients with disseminated histoplasmosis [2]. They reviewed 
the findings in 11 nonimmunocompromised patients with iso-
lated CNS disease. All had chronic meningitis complicated by 
hydrocephalus. Detection of antibodies in the CSF by ID was 
the most sensitive method for diagnosis, positive in 7 of 8 (88%) 
patients. A single case with a negative antibody and culture was 
diagnosed by biopsy of a spinal cord mass. The authors con-
cluded that the detection of antibody in CSF by ID is a sensitive 
method for diagnosis of Histoplasma meningitis. In contrast, in 
our study CSF antibody testing by CF and ID was only positive 
in about half of all cases, and in less than two-thirds of immu-
nocompetent patients.
Immunocompromise increases fungal burden, which was 
reflected by a trend toward higher antigen concentration 
in immunocompromised than nonimmunocompromised 
patients. Immunocompromise also impairs antibody produc-
tion [7], which was confirmed in this study. However, using the 
EIA assay, antibody was detected in the CSF in 68% of immu-
nocompromised patients, including one in whom the antigen 
test was negative.
The specificity for detection of antigen in CSF was 97%. Cross-
reactions were not observed in patients with meningitis caused 
by Cryptococcus, Aspergillus, Candida, or Mycobacterium tuber-
culosis. Prior studies confirmed lack of cross-reactivity in cryp-
tococcal meningitis [14]. Antigen was detected in the CSF in 
patients with meningitis caused by Blastomyces, which contains 
cross-reactive antigens [7]. Antigen was detected in the CSF in 2 
patients with extra-CNS histoplasmosis. Contamination of the 
CSF with serum antigens caused by a traumatic lumbar punc-
ture or passive diffusion across an inflamed blood–brain barrier 
may have caused these positive results.
No cause for a false-positive antigen result at 2.2 ng/mL was 
apparent in the patient with a serum sickness–like allergic reac-
tion to antibiotic treatment for Helicobacter gastritis. However, 
the result was below the LOQ upon repeat testing. The result 
would not have been reported as positive in clinical testing at 
MiraVista Diagnostics because of excessive variability between 
the 2 results.
The specificity for detection of intrathecal antibody produc-
tion was 93%. Elevated levels of IgG antibodies were noted in 
the CSF in 3 of 12 (25%) patients with histoplasmosis without 
meningitis (Supplementary Table 1). These may be caused by 
contamination with antibodies present in the patient’s blood. 
Similar findings were noted in our earlier study of antibody 
detection by RIA [6]. One patient had cavitary histoplasmosis 
and a CF titer in serum of 1:16. The second patient presented 
with an intracranial hemorrhage complicated by Staphylococcus 
epidermidis meningitis caused by an infected intracranial pres-
sure monitor and had a CF titer in serum of 1:8 [6]. Cross-
reactions were noted in the CSF of patients with meningitis 
caused by blastomycosis or cryptococcosis.
Causes for positive antibody results in several patients with 
other conditions, including a case of tuberculous meningitis and 
of neurosarcoidosis are unknown. Histoplasmosis should be rig-
orously excluded before beginning immunosuppressive therapy 
for presumed neurosarcoidosis as failure to do so can be cata-
strophic. The specificity of antibody detection by ID was 100% 
but was performed in only 22 patients. Antibody was falsely pos-
itive by CF in 7% of patients, supporting earlier findings [6].
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A major limitation of this study is its retrospective design and 
incomplete clinical and laboratory information. As CNS histo-
plasmosis is rare, a prospective study is not feasible. Another 
important limitation is incorporation bias caused by reliance 
on the use of MiraVista antigen EIA for diagnosis. However, 
excluding patients in which antigen results were used for diag-
nosis, representing one-third of cases, would limit the ability of 
the study to determine the role for antibody detection using the 
new EIA. Furthermore, the proportion of patients with positive 
antigen results was the same (78%) in all cases and in the sub-
set excluding detection of antigen as the sole basis of diagno-
sis. More information is needed to determine the specificity of 
these methods in patients with neurosarcoidosis, tuberculosis, 
and other types of fungal meningitis.
In conclusion, CNS histoplasmosis should be included in the 
differential diagnosis in patients with subacute or chronic men-
ingitis. Testing CSF for antigen and anti-Histoplasma antibodies 
by EIA provides the highest diagnostic yield with a sensitivity 
of 98% and a specificity of 90%. False-positive results, while 
uncommon, may occur with extra-CNS histoplasmosis, certain 
other fungal diseases, and unknown causes. Antibody testing 
by ID is also recommended because of its higher specificity and 
PPV (100%), but its lower sensitivity (44%) must be recognized. 
While the sensitivity for culture is low, cultivation remains the 
gold standard for confirming the diagnosis of CNS histoplas-
mosis, and may be the only basis for diagnosis in some cases. 
Culture should be performed by plating at least 10 mL of CSF 
using media suitable for isolation of Histoplasma and methods 
capable of detecting slow-growing organisms [15]. Repeat CSF 
analysis and brain or meningeal biopsy should be considered in 
patients with persistent findings if the initial tests are nondiag-
nostic, particularly if immunosuppressive therapy is considered 
or the patient is severely ill and diagnosis cannot be delayed [15].
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